Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca, Ardelyx Target Kidney Disease
by Lisa M. Jarvis
October 15, 2012
| A version of this story appeared in
Volume 90, Issue 42
AstraZeneca will pay $35 million up front for access to Ardelyx’ inhibitors of NHE3, a protein needed for the absorption of sodium in the intestines. The deal includes RDX5791, an NHE3 blocker that has completed a midstage study as an irritable bowel syndrome treatment and is poised for Phase II studies to treat kidney disease. Fremont, Calif.-based Ardelyx could reap another $237.5 million in milestones as compounds reach the market. AstraZeneca is taking on remaining development costs for RDX5791.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter